SCHEMBL12696201

SCHEMBL12696201

Nc1cncc(-c2c[nH]c3ccc(-c4nnc(N)s4)cc23)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 20/20 1.00
PIM3 Q86V86 20/20 1.00
PIM2 Q9P1W9 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12615310 0.89 PIM1 (0.80) PIM1PIM3PIM2
SCHEMBL12615071 0.86 PIM1 (1.00) PIM1PIM3PIM2
SCHEMBL12616097 0.86 PIM1 (1.00) PIM1PIM3PIM2
SCHEMBL12696114 0.85 PIM1 (1.00) PIM1PIM3PIM2
SCHEMBL15844230 0.84 PIM1 (1.00) PIM1PIM3PIM2
SCHEMBL12615163 0.84 PIM1 (1.00) PIM1PIM3PIM2
SCHEMBL12614744 0.84 PIM1 (1.00) PIM1PIM3PIM2
SCHEMBL12695997 0.84 PIM1 (1.00) PIM1PIM3PIM2
SCHEMBL12615298 0.84 PIM1 (1.00) PIM1PIM3PIM2
SCHEMBL15844763 0.84 PIM1 (1.00) PIM1PIM3PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9321756-B2 Azole compounds as PIM inhibitors AMGEN INC. (US) 2016-04-26 US disclosed
US-9321756-B2 Azole compounds as PIM inhibitors AMGEN INC. (US) 2016-04-26 US disclosed
US-20140187553-A1 Azole Compounds as PIM Inhibitors AMGEM INC. (US) 2014-07-03 US disclosed
US-20140187553-A1 Azole Compounds as PIM Inhibitors AMGEM INC. (US) 2014-07-03 US disclosed
WO-2012129338-A1 AZOLE COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140187553-A1 Azole Compounds as PIM Inhibitors PIM1, PIM3, PIM2 PIM1 1/4885PIM3 2/4885PIM2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.